Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Spero Therapeutics, Inc. | spro-ex322_9.htm |
| EX-31.2 - EX-31.2 - Spero Therapeutics, Inc. | spro-ex312_8.htm |
| EX-31.1 - EX-31.1 - Spero Therapeutics, Inc. | spro-ex311_6.htm |
| EX-10.1 - EX-10.1 - Spero Therapeutics, Inc. | spro-ex101_166.htm |
| 10-Q - 10-Q - Spero Therapeutics, Inc. | spro-10q_20200331.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Spero Therapeutics, Inc. (the “Company”) for the period ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
Date: May 8, 2020 |
|
By: |
/s/ Ankit Mahadevia, M.D. |
|
|
|
|
Ankit Mahadevia, M.D. |
|
|
|
|
President and Chief Executive Officer (Principal Executive Officer) |